In the following video, Motley Fool health-care analyst David Williamson looks at two major pieces of news surrounding biotech company Gilead (NASDAQ:GILD) that show that the company has a bright future ahead. He discusses another 100% cure rate for the company in the hepatitis-C space, and a new once-daily HIV drug for the company, with a better safety profile than the competition.